Event

PEGS Europe 2025

November 11 - 13, 2025
Lisbon, Portugal

Introduction

Advance your Biologics Discovery with Cutting-Edge Bruker Technology at PEGS Europe 2025!

Register today to explore Bruker’s unparalleled portfolio of analytical technologies for Biologics development. Our cutting-edge optofluidic and biophysical platforms unlock new possibilities in your discovery workflows. Capabilities range from single B cell and T cell screening to high-throughput epitope binning to kinetic measurements directly on cells. Accelerate your research with the innovative tools trusted by leading scientists and pharmaceutical innovators around the globe. Find out more below.

Event Highlights

  • Meet us at Booth 328: We're looking forward to meeting you in front of our biosensors and Beacon® solutions that will be on display at our booth. Take the chance to discuss with our experts how our solutions can help you in current and future projects.
  • Exhibitor Tutorials: Attend our tutorial sessions hosted by Bruker's expert team to discover the latest on Bruker’s Biosensors and Beacon antibody screening solutions.
  • Beacon® Live Demo at LxBio Ab: Come see a live demo of a Beacon® system and observe single B cell antibody discovery happen in real time at LxBio’s world-class services lab in Lisbon.

Bruker Biosensors Tutorial, November 12, 3:05 – 3:20 pm  

Biophysical characterization of antibodies against membrane proteins: from high-throughput screening to on-cell kinetics

Location: Engineering Antibodies and Beyond Track

As antibody formats grow more complex, precise biophysical characterization becomes essential. We present a workflow combining high-throughput SPR for epitope binning and interaction screening, switchSENSE® for affinity vs. avidity and ternary complex detection, and single-cell Interaction Cytometry for real-time kinetics on living cells in native context. Together, these tools support informed antibody design and selection.


Speaker:

Sven Malik
Senior Application Specialist, Bruker Biosensors, Munich, Germany

Sven studied Bioprocess Engineering at the Technical University of Dresden, Germany and graduated in 2012. During his diploma studies he investigated the interaction of cytomegalovirus protein pp65 against certain antibodies. In 2012 he joined Sierra Sensors GmbH to start his role as application specialist. After 6 years he became senior application specialist as Bruker acquired Sierra Sensors GmbH. Currently he is involved in customer support and business development.

Bruker Cellular Analysis Tutorial, November 11, 10:00 – 10:30 am

Function Beyond Binding: Discovering Internalizing Antibodies and Screening T Cell Engager Libraries

Location: Antibody-Based Therapies Track

Traditional antibody discovery focuses on identifying monoclonal antibody binders, while pushing functional characterization into later, more expensive screening. The Beacon® optofluidic platform, including the newest accessible Beacon Discovery™ system, enable researchers to characterize antibodies for function first and expand beyond single B cell screening to address ever-evolving biologic modalities and MOAs. We will highlight several case studies, including internalizing anti-PD-L1 antibody discovery and T cell engager library screening for cytotoxicity. 


Speakers:

Tiago Santos, Ph.D., MBA
Market Development Specialist, Bruker Cellular Analysis, Emeryville, CA, USA

Tiago Santos has over five years of experience in market development and is a member of the commercial team at Bruker Cellular Analysis. With a Ph.D. in Proteomics, his research focused on pathogen understanding through next-generation proteomics. For the past four years, he has been driving the promotion of Single Cell Functional platforms for Cell Therapy development and Antibody discovery, helping to advance cutting-edge solutions in the field.

Jacques Fieschi, Ph.D.
Chief Scientific Officer, MImAbs SAS, Marseille, France

Jacques Fieschi, Ph.D. in immunology (University of Aix-Marseille/CNRS) and former postdoctoral fellow at the French Atomic Energy Commission, worked at Beckman Coulter on the specificity of anti-steroid antibodies and the development of diagnostic tests. After joining QIAGEN-Marseille as head of project management, he helped found HalioDx, a pioneer in immuno-oncology diagnostics, where he headed R&D and initiated contract research activities for the pharmaceutical and biotech industries. His teams' innovations include Brightplex® technology (multiplex IHC), the application of AI to the discovery of biomarkers on histological section images, and the development of original high-throughput DNA/RNA sequencing methods. These tools are used to monitor clinical trials. 

Beacon® Live Demo – November 11, 12:15 – 1:50 pm

Live Single B Cell Antibody Discovery in Real Time

Location: Professor Gama Pinto Avenue 1649-003 Lisbon - Portugal

Join us for an off-site live demonstration of the Beacon® system performing single B cell antibody discovery. Experience how LxBio Ab uses their Beacon® to rapidly assess antigen specificity in under 30 minutes and meet experts from Bruker Cellular Analysis and LxBio to discuss how optofluidics changes the game. Transportation to and from PEGS Europe and lunch will be provided – please register soon to secure your spot as space is limited!

Learn more about the solutions Bruker is showcasing at PEGS Europe 2025

Disclaimer

As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regard to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.

*Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a non-governmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.

**A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.

 

For Research Use Only. Not for use in clinical diagnostic procedures.